ESTUDIO OBSERVACIONAL PROSPECTIVO MULTICÉNTRICO ALEATORIZADO PARA COMPARAR EL TRASPLANTE DE SANGRE DE CORDÓN UMBILICAL DE DONANTE NO EMPARENTADO VS TRASPLANTE DE PROGENITORES HEMATOPOYÉTICO DE DONANTE FAMILIAR HAPLOIDÉNTICO EN PACIENTES ADULTOS CON NEOPLA SIAS HEMATOLÓGICAS.

Review. 10.1080/17512433.2019.1573668. 2019

Decitabine as Salvage Therapy after Azacitidine in AML

De La Fuente, A; (...); Montesinos, P

Meeting Abstract. 2019

Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.

Montesinos, Pau, Sossa-Melo, Claudia

Article. 10.1016/S2352-3026(23)00308-3. 2023

DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Ibanez, M.; (...); Cervera, J.

Meeting Abstract. 2016

DESCRIPTIVE STUDY OF THE RECORD OF THROMBOTIC MICROANGIOPATHY IN A SINGLE CENTRE

Romero Dominguez, S.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Roboz GJ; (...); Kantarjian H

Article. 10.2217/fon.15.326. 2016

Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1016/j.jiac.2019.03.007. 2019

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.

Stojkov I; (...); Siebert U

Article. 10.1182/bloodadvances.2022008360. 2023

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.

Hernández-Boluda JC; (...); Yakoub-Agha I

Article. 10.1038/s41375-020-0815-z. 2020

Determinants of Survival in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Study by the Chronic Malignancies Working Party of EBMT

Hernandez-Boluda, JC; (...); Yakoub-Agha, I

Meeting Abstract. 2020

Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry.

Shouval R; (...); Nagler A

Article. 10.1016/S2352-3026(20)30394-X. 2021

DEVELOPMENT OF A CELLULAR MODEL OF ACUTE MYELOID LEUKEMIA THROUGH CRISPR/CAS 9 TECHNOLOGY

Romero, EG; (...); Zamora, JVC

Meeting Abstract. 2017

Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.

Rochau U; (...); Stauder R

Article. 10.1111/bjh.16654. 2020

DEVELOPMENT OF A MASSIVE SEQUENCING TEST FOR THE SIMULTANEOUS DETECTION OF POTENTIAL MUTATIONS AND CHROMOSOMAL ALTERATIONS IN PATIENTS WITH MYELODISPLASIC SYNDROMES

Liquori, A.; (...); Zamora, JVC

Meeting Abstract. 2017

Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model

Diaz-Garcia, C; (...); Pellicer, A

Article. 10.1093/humrep/dez115. 2019

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner H; (...); Bloomfield, CD

Review. 10.1182/blood-2016-08-733196. 2017

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults Recommendations From the European Hematology Association and the European LeukemiaNet

Itzykson, R; (...); European LeukemiaNet

Article. 10.1097/HS9.0000000000000150. 2018

DIAGNOSIS OF NOONAN SYNDROME AFTER STUDY OF NGS BY ESSENTIAL THROMBOCITEMIA

Marco Ayala, J.; (...); Sanz, M. A.

Meeting Abstract. 2018

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Spanish PETHEMA Grp

Article. 10.4084/MJHID.2019.016. 2019

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.

Montesinos P; (...); DiNardo CD

Article. 10.1182/bloodadvances.2023011914. 2024

Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.

Fathi, Amir T; (...); de Botton, Stephane

Review. 10.1002/ajh.26142. 2021

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

Miyazaki, Y; (...); Greenberg, PL

Article. 10.1016/j.leukres.2018.08.022. 2018

Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)

Santini, Valeria; (...); Zeidan, Amer M.

Meeting Abstract. 10.1182/blood-2022-160282. 2022

Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.

Asensi Cantó P; (...); Guerreiro M

Article. 10.1111/tid.14067. 2023

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Sanz GF, Ibañez M, Such E

Article. 10.1182/bloodadvances.2019000680. 2019

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

Suárez EU; (...); Montesinos P

Article. 10.1007/s00277-024-05840-7. 2024

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Azibeiro Melchor, Raul; (...); Ossenkoppele, Gert J.

Meeting Abstract. 10.1182/blood-2021-150766. 2021

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Hutchings, Martin; (...); Subklewe, Marion

Meeting Abstract. 10.1182/blood-2023-173302. 2023

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/17512433.2023.2174523. 2023

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Review. 10.1007/s00277-020-04186-0. 2020

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Pfeilstocker, Michael; (...); Greenberg, Peter L.

Meeting Abstract. 10.1182/blood-2022-158671. 2022

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Itzykson, R; (...); European MDS Registry Members

Article. 10.1182/bloodadvances.2018020495. 2018

Economic Burden of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Spanish Multicenter, Retrospective Study

Vazquez, L; (...); Solano, C

Meeting Abstract. 2020

Editorial introductions

Curigliano, Giuseppe; (...); Mateos, Maria-Victoria

Editorial Material. 10.1097/CCO.0000000000001001. 2023

Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies

Moscardó F; (...); Sanz GF

Article. 10.1016/j.bbmt.2014.06.038. 2014

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

Dinardo, CD; (...); Dohner, H

Meeting Abstract. 2020

Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (RR) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2019

EFFECT OF MISSENSE MUTATIONS IN THE SPLICING OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA

Morote-Faubel, M.; (...); Cervera, J.

Meeting Abstract. 2019

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7006. 2021

EFFECTIVENESS AND SAFETY OF THE INFUSION OF DONOR LYMPHOCYTES AFTER HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOYETIC PROGENITOR CELLS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: MULTICENTRIC RETROSPECTIVE STUDY OF THE HEMATOPETIC SPANISH TRIPASHOLE GROUP

Martin-Sanchez, Guillermo; (...); Bermudez, Aranzazu

Meeting Abstract. 2020

EFFECTIVENESS AND TOXICITY OF THE USE OF INOTUZUMAB (INO) IN PATIENTS WITH RESISTANT OR RECALLING (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (LAL). STUDY OF PATIENTS INCLUDED IN INO'S EXPANDED USE PROGRAM

Ribera Santasusana, J. M.; (...); Valero, M.

Meeting Abstract. 2021

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply

Bernal, T; (...); Sanz, G

Letter. 10.1038/leu.2015.339. 2016

Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry

Bernal T; (...); Spanish Society of Hematology

Article. 10.1038/leu.2015.115. 2015

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Pleyer, Lisa; (...); Greil, Richard

Meeting Abstract. 10.1182/blood-2019-123941. 2019

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.

Zeiser R; (...); Chen YB

Article. 10.1016/S2352-3026(21)00367-7. 2022

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301) : a randomised, multicentre, double-blind, phase 3 trial

Zeiser, Robert; (...); Chen, Yi-Bin

Article. 10.1016/S2352-3026(21)00367-7. 2022

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Ribera, JM; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1397661. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1182/blood-2018-99-110439. 2018

Efficacy and Safety of Single-Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 2019

Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Jonas, BA; (...); Levis, MJ

Meeting Abstract. 10.1016/j.clml.2019.07.097. 2019

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/14728214.2021.2009800. 2022

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.

Smith CC; (...); Bahceci E

Article. 10.1182/blood-2019-122620. 2019

Emerging strategies for the treatment of older patients with acute myeloid leukemia

Sanz MA; (...); Venditti A

Review. 10.1007/s00277-016-2666-2. 2016

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

DiNardo CD; (...); Döhner H

Article. 10.1016/S1470-2045(21)00494-0. 2021

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

de Botton, Stephane; (...); DiNardo, Courtney D.

Article. 10.1182/blood.2021014901. 2022

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Montesinos, Pau; (...); Recher, Christian

Meeting Abstract. 10.1182/blood-2024-194356. 2024

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Meeting Abstract. 10.1182/blood-2023-180691. 2023

Enhancing roasted pepper quality sustainably: Impact of biodegradable mulches

Guerra, Marcos; (...); Casquero, Pedro Antonio

Article. 10.1016/j.jafr.2024.101393. 2024

Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

Calvo, X; (...); Florensa, L

Article. 10.1002/ajh.24732. 2017

Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)

Segui, Ines Gomez; (...); Garma, Julio Del Rio

Meeting Abstract. 2024

Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation

Sanz J, Andreu R

Review. 10.1097/CCO.0000000000000119. 2014

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes

Calvo X; (...); Florensa L

Article. 10.1038/modpathol.2016.146. 2016

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome

Garelius, HKG; (...); Hellström-Lindberg E

Article. 10.1111/joim.12579. 2017

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.

Sanz, Jaime; (...); Ciceri, Fabio

Article. 10.1038/s41409-023-02075-4. 2023

Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies

Paviglianiti, A; (...); Rocha, V

Article. 10.1111/bjh.14962. 2017

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Lopez Cadenas, Felix; (...); Diez-Campelo, Maria

Meeting Abstract. 10.1182/blood-2022-168718. 2022

EVALUATION OF THE MUTATION OF FLT3 IN ACUTE MYELOID LEUKAEMIA: RESULTS OF THE DELPHI QUESTIONNAIRE OF THE SPANISH GROUP

Gomez-Casares, M. T.; (...); Sierra, J.

Meeting Abstract. 2019

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Mosquera Orgueira, Adrian; (...); Perez Encinas, Manuel Mateo

Article. 10.3389/fonc.2022.968340. 2022

Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.

Bazarbachi A; (...); Mohty M

Article. 10.1158/1078-0432.CCR-20-3134. 2020

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications

Remacha ÁF; (...); Sanz G

Article. 10.1007/s00277-014-2274-y. 2015

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan

Meeting Abstract. 10.1182/blood-2022-163016. 2022

Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.

Labrador, Jorge; (...); Montesinos, Pau

Article. 10.1002/cncr.35431. 2024

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

Boluda B; (...); Montesinos P

Article. 10.1080/10428194.2021.1938031. 2021

Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1038/s41375-020-01058-4. 2020

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

Montoro, Juan; (...); Sanz, Jaime

Article. 10.1111/ejh.13529. 2021

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Madry, K; (...); Smith, A

Meeting Abstract. 10.1182/blood-2018-99-115928. 2018

Excess mortality in the myelodysplastic syndromes

Nomdedeu, M; (...); Spanish MDS Group

Article. 10.1002/ajh.24606. 2017

Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)

Expert Panel of GESIDA and the National AIDS Plan; (...); Rivero A

Article. 10.1016/j.eimc.2015.03.017. 2015

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Pemmaraju, Naveen; (...); Daver, Naval

Meeting Abstract. 10.1182/blood-2021-146666. 2021

EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A GLOBAL MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: PRELIMINARY RESULTS FROM THE HLALOSS COLLABORATIVE STUDY

Vago, Luca; (...); Fleischhauer, Katharina

Meeting Abstract. 2018

Exploiting Cutting-Edge Technologies to Analyze Loss of HLA in a Global Multicentric Cohort of Post-Transplantation Relapses: Preliminary Results from the HLALOSS Collaborative Study

Vago, Luca; (...); Fleischhauer, Katharina

Meeting Abstract. 2018

EXPLOITING CUTTING-EDGE TECHNOLOGIES TO ANALYZE LOSS OF HLA IN A MULTICENTRIC COHORT OF POST-TRANSPLANTATION RELAPSES: RESULTS FROM THE HLALOSS GLOBAL COLLABORATIVE STUDY

Vago, L.; (...); Fleischhauer, K.

Meeting Abstract. 2018

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180710. 2023

EXTRACORPOREAL PHOTOPHERESIS IN GRAFT-VERSUS-HOST DISEASE.

Canto, Pedro Asensi; (...); Segui, Ines Gomez

Article. 10.1016/j.jtct.2023.07.001. 2023

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.1002/jca.21901. 2021

Ex-vivo T-cell depleted peripheral blood stem cell transplantation from HLA-matched sibling donors for the treatment of severe aplastic anemia

Cano-Ferri, I.; (...); Sanz, G.

Meeting Abstract. 2015

Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia

Sossa, Claudia; (...); Marcela Cuervo, Diana

Meeting Abstract. 2023

Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation

Solves P; (...); Carpio N

Article. 10.1007/s00277-017-3168-6. 2018

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Ribera JM; (...); Sancho JM

Article. 10.3324/haematol.2023.283342. 2024

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.leukres.2015.11.012. 2016

Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis

Fox, ML; (...); Valcarcel, D

Article. 10.1080/10428194.2020.1788015. 2020

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

Hernandez-Boluda, JC; (...); GELMC

Article. 10.1038/s41408-018-0125-0. 2018

Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Espanol De Trasplante y Terapia Celular (GETH-TC) Study

Fabbri, Nicole; (...); Mussetti, Alberto

Meeting Abstract. 10.1182/blood-2023-185721. 2023

FINAL RESULTS OF THE LAL-RI 08 PROTOCOL FOR ADOLESCENTS AND YOUNG ADULTS (AAJ) WITH LYMPHOBLASTIC ACUTE LEUKEMIA (LAL) OF STANDARD RISK (RE)

Santasusana, JMR; (...); Vale, AODCE

Meeting Abstract. 2018

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.

Zeidan, Amer M.; (...); Santini, Valeria

Article. 10.1038/s41375-022-01724-9. 2022

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).

Jabbour, Elias; (...); Ribera, Josep-Maria

Meeting Abstract. 2023

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

Jabbour, Elias; (...); Ribera, Jose-Maria

Meeting Abstract. 2023

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Salamero, Olga; (...); Somervaille TCP

Article. 10.1200/JCO.19.03250. 2020

FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET.

Venditti, Adriano; (...); Ossenkoppele, Gert J

Article. 10.1182/bloodadvances.2024013744. 2025

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

Spina M; (...); FLORENCE Study Group

Article. 10.1093/annonc/mdv317. 2015

Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes

Sánchez-Castro J; (...); Solé F

Article. 10.3109/10428194.2015.1028053. 2015

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

Pallarès V; (...); Casanova, I

Article. 10.3390/cancers10110436. 2018

Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7013. 2021

Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2022

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Perl AE; (...); Levis MJ

Article. 10.1182/blood.2021011583. 2022

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

Genesca, E; (...); Ribera, JM

Article. 10.1186/s13045-018-0639-8. 2018

FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS

Genesca, E; (...); Ribera, JM

Meeting Abstract. 2017

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Bazarbachi, Ali; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2024-204672. 2024

FREQUENCY AND IMPACT OF SOMATIC MUTATIONS ON OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY

Bazarbachi, Ali; (...); Mohty, Mohamad

Meeting Abstract. 2024

Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

Motllo C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2017.1326596. 2018

Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

Motlló C; (...); PETHEMA Group, Spanish Society of Hematology

Article. 10.1080/10428194.2016.1177182. 2017

Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain.

Ribera, Josep-Maria; (...); Pinana, Jose-Luis

Article. 10.1016/j.clml.2021.06.024. 2021

Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)

Garcia Cadenas, Irene; (...); Solano, Carlos

Meeting Abstract. 2018

Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran

Article. 10.1111/ejh.13226. 2019

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Cortes, JE; (...); Baer, MR

Meeting Abstract. 10.1182/blood-2018-99-114126. 2018

FUNCTIONAL CLASSIFICATION OF DEEP INTRONIC VARIANTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2019

FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Morote-Faubel, Mireya; (...); Cervera, Jose

Meeting Abstract. 2020

FUNCTIONAL STUDY OF SILENCED HMGCR GENE IN CELL LINES OF ACUTE MYELOID LEUKEMIA PATIENTS

De Matteo, B; (...); Zamora, JVC

Meeting Abstract. 2017

GAM: General Auxetic Metamaterial with Tunable 3D Auxetic Behavior Using the Same Unit Cell Boundary Connectivity

Ben-Yelun, Ismael; (...); Saucedo-Mora, Luis

Article. 10.3390/ma16093473. 2023

Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

Eirís J; (...); Sanz J

Article. 10.1016/j.jtct.2024.10.009. 2024

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial

Ravandi, Farhad; (...); Dombret, Herve

Meeting Abstract. 2020

Gastrointestinal events and management strategies for patients with acute myeloid leukemia (AML) in first remission receiving oral azacitidine (Oral-AZA) in the randomized, placebo-controlled, phase 3 QUAZAR AML-001 maintenance trial

Pfeilstocker, M.; (...); Dombret, H.

Meeting Abstract. 2021

Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

Mosquera Orgueira A; (...); Bello López JL

Article. 10.1371/journal.pone.0247093. 2021

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

D'Amico, Saverio; (...); Della Porta, Matteo Giovanni

Meeting Abstract. 10.1182/blood-2024-209541. 2024

GENES BELONGING TO THE SWI/SNF CHROMATIN REMODELING COMPLEXES ARE MUTATED AT HIGH FREQUENCY IN RARE T(11;17)(Q23;Q21)/ZBTB16-RARA ACUTE MYELOID LEUKEMIA PATIENTS

Fabiani, E.; (...); Voso, M. T.

Meeting Abstract. 2020

GENOME-WIDE ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISM (SNPS) IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE

Ibanez, M.; (...); Cervera, J.

Meeting Abstract. 2016

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)

Lin, Wei-Yu; (...); Allan, James M.

Article. 10.1038/s41467-021-27679-6. 2022

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Lin WY; (...); Allan JM

Article. 10.1038/s41467-021-26551-x. 2021

GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

Bernard, E.; (...); Papaemmanuil, E.

Meeting Abstract. 10.1016/j.leukres.2023.107146. 2023

Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain

Lalaoui, R; (...); Rolain, JM

Article. 10.1186/s13756-019-0630-3. 2019

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil, Celia; (...); Genesca, Eulalia

Article. 10.3324/haematol.2022.281196. 2023

Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.

Mannan A; (...); Aljurf M

Article. 10.1016/j.hemonc.2020.05.007. 2020

Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction

Chen-Liang, TH; (...); Jerez, A

Meeting Abstract. 10.1182/blood-2018-99-116045. 2018

GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS

Santiago, M.; (...); Cervera-Zamora, J.

Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023

GETH-CLL4: Long-term follow-up of a pilot trial evaluating the addition of ofatumumab to the conditioning regimen of patients with chronic lymphocytic leukemia undergoing allogeneic HCT

Montesinos, Pau; (...); Delgado, Julio

Meeting Abstract. 2018

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.

Perl AE; (...); Levis MJ

Article. 10.1056/NEJMoa1902688. 2019

Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML comutations or a high FLT3-internal tandem duplication allelic ratio

Levis, MJ; (...); Bahceci, E

Meeting Abstract. 2020

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial

Perl, AE; (...); Levis, MJ

Meeting Abstract. 10.1158/1538-7445.AM2019-CT184. 2019

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial

Perl, A. E.; (...); Levis, M. J.

Meeting Abstract. 2019

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Ballesta-López O; (...); Montesinos P

Review. 10.2217/fon-2020-0700. 2020

Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.

Sekeres MA; (...); Cortes JE

Article. 10.1038/s41375-023-02001-z. 2023

Glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): BRIGHT AML 1003 final report and 4-year overall survival follow-up

Heuser, M; (...); Cortes, JE

Meeting Abstract. 2020

Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up

Heuser, Michael; (...); Cortes, Jorge E.

Meeting Abstract. 2020

Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone

Wang, ES; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.114. 2019

Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.

Andres Regino, Carlos; (...); Angel Sanz, Miguel

Article. 10.1159/000528088. 2023

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.

Roboz GJ; (...); Döhner H

Article. 10.1182/bloodadvances.2023012062. 2024

Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia.

Lozano ML, Sanz MA, Vicente V

Article. 10.1016/j.medcli.2021.03.017. 2021

Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

Kwon M; (...); Diez-Martin JL

Article. 10.1038/bmt.2017.36. 2017

Haploidentical non-manipulated stem cell transplant in patients with non-hodgkin lymphoma: Spanish experience

Dorado, N; (...); Diez-Martin, JL

Meeting Abstract. 2019

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.

Sanz, Jaime; (...); Ciceri, Fabio

Article. 10.1182/bloodadvances.2023012133. 2024

Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Non-Hodgkin Lymphoma: The Spanish Experience

Dorado, N; (...); Kwon, M

Meeting Abstract. 2020

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers A Systematic Review and Meta-analysis

Gagelmann, N; (...); Kroger, N

Review. 10.1001/jamaoncol.2019.3541. 2019

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1097/HS9.0000000000000790. 2022

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Nagler, Arnon; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-144558. 2021

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Sobas, Marta; (...); Maria Hernandez-Rivas, Jesus

Meeting Abstract. 10.1182/blood-2021-149521. 2021

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

Solana-Altabella A; (...); Montesinos P

Article. 10.1111/ejh.13604. 2021

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

DiNardo, Courtney D.; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-147601. 2021

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Dinardo, Courtney Denton; (...); De Botton, Stephane

Meeting Abstract. 2022

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

Stauder, R; (...); de Witte, T

Article. 10.1038/s41375-018-0089-x. 2018

HEALTH-RELATEDQUALITYOF LIFE IS SUBSTANTIALLY IMPAIRED IN LOWER-RISK MDS WHEN COMPARED WITH REFERENCE POPULATIONS AND SIGNIFICANTLY AFFECTS OVERALL SURVIVAL

Stauder, R; (...); De Witte, T

Meeting Abstract. 10.1016/S0145-2126(17)30135-2. 2017

Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.

Dohner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 2022

Hematologic neoplasms: interpreting lung findings in chest computed tomography.

Calvillo Batllés P; (...); Compte Torrero L

Article. 10.1016/j.rx.2015.07.003. 2015

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

Huang XJ; (...); Issaragrisil S

Article. 10.18632/oncotarget.15655. 2017

Hematopoietic Stem cell transplant in Aplastic anemia in patients older than 40 years: The experience of the Spanish Group of Hematopoietic Stem Cell Transplant (GETH)

Yanez, Lucrecia; (...); Solano, Carlos

Meeting Abstract. 2018

Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.

Sanz, Jaime; (...); Marrow Transplantation (EBMT)

Article. 10.1038/s41409-020-01162-0. 2020

Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.

Ruggeri A; (...); Nagler A

Article. 10.1038/s41409-019-0582-5. 2019

HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY

Bastida Bermejo, J. M.; (...); Diez-Campelo, M.

Meeting Abstract. 2016

High Delta Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia

Lucena-Araujo AR; (...); Rego EM

Article. 10.1182/blood-2015-01-623330. 2015

High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous $\beta$-Lactams.

Djukovic, Ana; (...); Ubeda, Carles

Article. 2020

High heterogeneity of multidrug-resistant Enterobacteriaceae fecal levels in hospitalized patients is partially driven by intravenous beta-lactams.

Djukovic A; (...); Ubeda C

Article. 10.1128/AAC.01415-19. 2020

Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Baron, Frederic; (...); Ciceri, Fabio

Article. 10.1002/ajh.27466. 2024

History of Acute Promyelocytic Leukemia.

Sanz MA, Barragán E

Article. 10.2991/chi.k.210703.001. 2021

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M; (...); Zeidan AM

Article. 10.1182/bloodadvances.2018016121. 2018

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2021-152183. 2021

Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.

Salamero, Olga; (...); Montesinos, Pau

Article. 10.1016/S2352-3026(24)00132-7. 2024

Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial.

Konopleva, Marina Y.; (...); Wei, Andrew H.

Article. 10.1182/bloodadvances.2021006303. 2022

Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia

Pinero, Paula; (...); Tarin, Fabian

Article. 10.3390/cancers14164010. 2022

Identifying prognostic gene panels in acute myeloid leukemia.

Sanchez-Garcia, Joaquin; (...); Montesinos, Pau

Article. 10.1080/17474086.2023.2193322. 2023

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Review. 10.2147/BLCTT.S177913. 2019

IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION

Eiris, Juan; (...); Balaguer-Rosello, Aitana

Meeting Abstract. 2024

Imaging features and clinical data-based network analysis of CAR-T treated B- cell lymphoma patients in relation to their TP53 mutation status

Estepa-Fernandez, A.; (...); Alberich-Bayarri, A.

Meeting Abstract. 2024

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.

Cordón L; (...); Sanz J

Article. 10.1007/s00277-024-05758-0. 2024

Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy.

Szabolcs, Paul; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.04.018. 2023

Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch.

Santiago, M; (...); Solves, P

Letter. 10.1111/tme.12538. 2019

Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3-Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 10.1182/blood-2022-169011. 2022

IMPACT OF ALLO-HCT IN FIRST COMPLETE REMISSION (CR1) IN ADDITION TO FLT3 INHIBITION WITH QUIZARTINIB IN AML WITH FLT3-ITD: RESULTS FROM THE QUANTUM-FIRST TRIAL

Schlenk, Richard F.; (...); Erba, Harry P.

Meeting Abstract. 2023

IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML

Sanz, Jaime; (...); Ciceri, Fabio

Meeting Abstract. 2023

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols.

Barba P; (...); Ribera JM

Article. 10.1097/HS9.0000000000000810. 2023

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Article. 10.1080/10428194.2020.1839650. 2020

Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation

Cunha R; (...); Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of t

Article. 10.1182/blood-2016-06-722249. 2017

IMPACT OF CYTOGENETIC ABNORMALITIES DEFINING AML MYELODYSPLASIA-RELATED (WHO AND ICC 2022) IN FIRST LINE DECITABINE IN UNFIT AML PATIENTS

de la Fuente, Adolfo; (...); Tormo, Mar

Meeting Abstract. 2023

Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1016/j.jtct.2022.08.018. 2022

Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.

Ayala, Rosa; (...); Montesinos, Pau

Article. 10.3390/cancers14235799. 2022

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Matteuzzi, Tommaso; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-152215. 2021

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

Rubio, MT; (...); Nagler, A

Article. 10.1186/s13045-016-0389-4. 2017

Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort

Stahl, M; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-112495. 2018

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop

Article. 10.1038/s41375-021-01126-3. 2021

Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1111/bjh.18765. 2023

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018

Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation

Rodriguez-Veiga, R.; (...); Sanz, M. A.

Meeting Abstract. 2015

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017

Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.

Döhner K; (...); Bloomfield CD

Article. 10.1182/blood.2019002697. 2020

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Torrent, Anna; (...); Barba, Pere

Meeting Abstract. 10.1182/blood-2023-186388. 2023

IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Marco-Ayala, Javier; (...); Solves, Pilar

Article. 10.1016/j.jtct.2023.01.009. 2023

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L; (...); EUMDS Registry Participants

Article. 10.3324/haematol.2018.212217. 2020

IMPACT OF RED BLOOD CELL TRANSFUSIONS ON SURVIVAL IN LOWER-RISK MDS PATIENTS INCLUDED IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY

de Swart, L; (...); de Witte, T

Meeting Abstract. 10.1016/S0145-2126(17)30393-4. 2017

Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study.

Oreiro MB; (...); García-Sancho AM

Article. 10.1016/j.jtct.2023.08.026. 2023

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Bastos-Oreiro, Mariana; (...); Martin Garcia-Sancho, Alejandro

Meeting Abstract. 10.1182/blood-2022-166329. 2022

IMPACT OF THE TREATMENT OF THE PURE APLASIA OF THE RED SERIES; EXPERIENCE IN A CENTER

Marco, Ayala Javier; (...); Solves, Alcaina Pilar

Meeting Abstract. 2020

Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia

Barba P; (...); Ribera JM

Article. 10.3109/10428194.2015.1014365. 2015

Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Meeting Abstract. 2015

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M; (...); EUMDS Registry Participants

Article. 10.3324/haematol.2018.212332. 2020

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.

Kayser, Sabine; (...); Schlenk, Richard F.

Article. 10.3324/haematol.2022.282127. 2023

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Marconi, Giovanni; (...); Martinelli, Giovanni

Meeting Abstract. 10.1182/blood-2023-184745. 2023

IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING

Simarro, CS; (...); Gonzalez, EB

Meeting Abstract. 2017

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)

Bernard, Elsa; (...); Elias, Harold K

Article. 10.1038/s41591-021-01367-w. 2021

Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E; (...); Papaemmanuil, E

Article. 10.1038/s41591-020-1008-z. 2020

Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil

de la Rubia, Javier; (...); Sanz, Miguel

Meeting Abstract. 2023

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.

Onecha E; (...); Ayala R

Article. 10.1111/bjh.16432. 2020

In MDS, is higher risk higher reward?

Sanz GF

Article. 10.1182/hematology.2019000042. 2019

In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene

Such E; (...); Sanz MA

Letter. 10.1007/s00277-014-2073-5. 2014

IN VIVO MODELS FOR THE FUNCTIONAL STUDY OF CO-OCCURRING GENETIC AND EPIGENETIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES

Martinez-Valiente, C.; (...); Sanjuan-Pla, A.

Meeting Abstract. 2018

IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES

Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra

Meeting Abstract. 2020

INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING THE THERAPY OF INDUCTION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. STUDY OF 67 PATIENTS FROM A SINGLE CENTRE

Martinez Garcia, M. F.; (...); Sanz Alonso, M. A.

Meeting Abstract. 2015

Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

Ribera, Josep-Maria; (...); Feliu, Evarist

Article. 10.1002/cncr.32156. 2019

Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.

Rodríguez-Veiga R; (...); Sanz GF

Article. 10.1007/s00277-019-03744-5. 2019

Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.

Castillo MI; (...); Díaz TM

Article. 10.1002/cam4.6300. 2023

Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis

Montesinos P; (...); Sanz MA

Article. 10.1038/bmt.2015.181. 2015

Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study

Vago, L; (...); Fleischhauer, K

Meeting Abstract. 10.1182/blood-2018-99-112142. 2018

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Kelleher, N; (...); Spanish Soc Hematology

Article. 10.3109/10428194.2015.1040013. 2016

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Sirenko, Maria; (...); Papaemmanuil, Elli

Meeting Abstract. 10.1182/blood-2022-162397. 2022

Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.

Asensi Cantó P; (...); Sanz J

Article. 10.1038/s41409-024-02391-3. 2024

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients

Pinana, JL; (...); Navarro, D

Article. 10.1111/tid.13158. 2019

Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2024.12.006. 2024

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.

Sobas, Marta; (...); Montesinos, Pau

Article. 10.1007/s00277-023-05582-y. 2023

Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials

Barba, P; (...); Ribera, JM

Article. 10.1111/ejh.13178. 2019

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph plus ALL.

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.6533. 2024

In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph plus ALL

Jabbour, Elias; (...); Ribera-Santasusana, Jose-Maria

Meeting Abstract. 10.1016/S2152-2650(24)00426-9. 2024

Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016

Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Labrador, Jorge; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-162591. 2022

Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation

Balaguer Rosello A; (...); Sanz, J

Article. 10.1016/j.bbmt.2016.10.005. 2017

INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN THE ALOGENIC TRANSPLANTATION OF HEMATOPOYETIC PROGENITORS

Balaguer Rosello, A.; (...); Sanz Caballer, J.

Meeting Abstract. 2018

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

Megías-Vericat JE; (...); Aliño SF

Review. 10.1038/tpj.2014.80. 2015

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Article. 10.1097/FPC.0000000000000431. 2021

Influence of Polymorphisms Related to Drug Metabolism in Allogeneic Bone Marrow Transplantation

Santiago, M; (...); Alino, S

Meeting Abstract. 2021

Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia

Meeting Abstract. 2015

Infusion of Haploidentical Stem Cell after Consolidation in Younger Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase I-II Study

Boluda, Blanca; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood.V128.22.1614.1614. 2016

INHIBITORS OF THE MUTATED DEHYDROGENASE (MIDH), IVOSIDENIB OR ENASIDENIB, IN COMBINATION WITH AZACITINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

Montesinos, P; (...); Vyas, P

Meeting Abstract. 2018

IN-SILICO AND IN VITRO STUDY OF MUTATIONS THAT ALTER THE SPLICING PROCESS IN PATIENTS WITH MYELODISPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2019

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.

Simoes C; (...); Paiva B

Article. 10.1182/bloodadvances.2022008141. 2023

INTENSIVE CHEMOTHERAPY VERSUS DECITABINE FIRST LINE LAM OVER 60 YEARS OLD

De la Fuente, A.; (...); Montesinos, P.

Meeting Abstract. 2019

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study

Lucena-Araujo AR; (...); Rego EM

Article. 10.1007/s00277-014-2142-9. 2014

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

Blanes, M; (...); de la Rubia, J

Letter. 10.1007/s00277-019-03663-5. 2019

Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study

Blanes, M; (...); de la Rubia, J

Meeting Abstract. 10.1016/j.clml.2019.09.473. 2019

Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study

Blanes, M; (...); de la Rubia, J

Meeting Abstract. 2019

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen

Montoro, J; (...); Pinana, JL

Article. 10.1111/ejh.13202. 2019

INVASIVE FUNGAL INFECTION IN ADULT PATIENTS SUBMITTED TO UMBILICAL CORD BLOOD TRANSPLANTATION

Montoro, J.; (...); Pinana, J. L.

Meeting Abstract. 2018

Investigation of HLA loss relapse after allogeneic stem cell transplantation in a global multicentric cohort (HLALOSS Consortium)

Fleischhauer, K; (...); Vago, L

Meeting Abstract. 2018

Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation

Solves, P; (...); Sanz, MA

Letter. 10.1111/tme.12386. 2017

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Im, Annie; (...); Pavletic, Steven Z.

Meeting Abstract. 10.1182/blood-2022-169605. 2022

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Montesinos, Pau; (...); Dohner, Hartmut

Article. 10.1056/NEJMoa2117344. 2022

Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.

Montesinos, Pau, de Botton, Stephane, Dohner, Hartmut

Letter. 10.1056/NEJMc2206489. 2022

Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study

de Botton, Stephane; (...); Doehner, Hartmut

Meeting Abstract. 2023

Killer Cell Immunoglobulin-Like Receptor Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia

Rocha, V; (...); Ctr Int Blood Marrow Transplant Re

Article. 10.1016/j.bbmt.2016.04.007. 2016

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Montesinos, Pau; (...); Dombret, Herve

Meeting Abstract. 10.1182/blood-2023-187286. 2023

Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation.

Bueno F; (...); Navarro D

Article. 10.1111/tid.13507. 2020

ladademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Salamero, Olga; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-168945. 2022

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.

Cruz, David; (...); Gallardo, David

Article. 10.3389/fimmu.2023.1066393. 2023

Live donor kidney transplantation. Situation analysis and roadmap.

de la Oliva Valentín M; (...); Domínguez-Gil B

Article. 10.1016/j.nefroe.2022.02.002. 2022

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.

Meeting Abstract. 10.1182/blood-2019-129274. 2019

Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy plus Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy

Caceres, S; (...); Burgues, JMMB

Meeting Abstract. 10.1182/blood-2018-99-116924. 2018

Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.

Sanz, Miguel Angel; (...); Sanz, Jaime

Article. 10.1038/s41409-024-02319-x. 2024

Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.

Gomez, E; (...); Fernandez-Rodriguez, C M

Article. 10.1111/apt.18004. 2024

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

Martínez-Cuadrón D; (...); Sanz MA

Article. 10.1038/leu.2017.178. 2018

Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1038/s41409-023-02012-5. 2023

Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Nagler, Arnon; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2022-156231. 2022

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato

Article. 10.1016/j.jtct.2020.12.029. 2021

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Recher, Christian; (...); Montesinos, Pau

Article. 10.1038/s41375-021-01425-9. 2022

Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP

Michallet, M; (...); Yakoub-Agha, I

Meeting Abstract. 2019

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.

Wei, Andrew H.; (...); Roboz, Gail J.

Letter. 10.1002/ajh.26847. 2023

Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Papayannidis, C; (...); Cortes, JE

Meeting Abstract. 10.1016/j.clml.2019.07.111. 2019

Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

Smith, BD; (...); Cortes, JE

Meeting Abstract. 2019

Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation

de Koning, Coco; (...); Nierkens, Stefan

Article. 10.1038/s41409-021-01417-4. 2021

LYMPHOPENIA IS HIGHLY PREVALENT IN MDS AND PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR IPSS-R VERY-LOW AND LOW-RISK PATIENTS. AN ANALYSIS FROM THE EU-MDS REGISTRY

Silzle, T.; (...); Smith, A.

Meeting Abstract. 2021

Lymphopenia is highly prevalent in MDS and provides prognostic information for IPSS-R (very)-low-risk patients. An analysis from the EU-MDS registry

Silzle, T.; (...); Smith, A.

Meeting Abstract. 2021

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-167138. 2022

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2023-183029. 2023

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner, Joshua F; (...); Vyas, Paresh

Article. 10.1182/blood.2024027408. 2025

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Sanz, MA; (...); Lo-Coco, F

Article. 10.1182/blood-2019-01-894980. 2019

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.

Onida F; (...); Pleyer L

Article. 10.1182/blood.2023023476. 2024

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Ravandi, F; (...); Dombret, H

Article. 10.1186/s13045-021-01142-x. 2021

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.

Stahl M; (...); Zeidan AM

Article. 10.1038/s41375-020-0783-3. 2020

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Bowen, David; (...); de Witte, Theo M.

Meeting Abstract. 10.1182/blood-2021-150322. 2021

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Smoljanovic, Inga Mandac; (...); Bowen, David

Meeting Abstract. 10.1182/blood-2022-167716. 2022

Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.

Brissot E; (...); Mohty M

Article. 10.1038/s41409-020-0970-x. 2020

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

Buske C; (...); Passamonti F

Article. 10.1016/j.esmoop.2022.100403. 2022

MASS SEQUENCING DIRECTED TO THE STUDY OF REARRANGEMENTS AND CHANGES IN GENIC EXPRESSION IN ACUTE MYELOID LEUKEMIA

Sargas Simarro, C.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

MATCHED RELATED VERSUS MATCHED UNRELATED VERSUS HAPLOIDENTICAL DONORS IN FLT3-ITD + AML PATIENTS IN CR1: A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY

Brissot, Eolia; (...); Ciceri, Fabio

Meeting Abstract. 2024

Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia

Sanz MA; (...); Perales A

Article. 10.1007/s00277-015-2372-5. 2015

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Oster, HS; (...); Mittelman, M

Meeting Abstract. 10.1182/blood-2018-99-111838. 2018

Measurable Residual Disease (MRD) Testing for Acute Leukemia in EBMT Transplant Centers: A Survey on Behalf of The ALWP of the EBMT

Nagler, A; (...); Mohty, M

Meeting Abstract. 2020

Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1038/s41409-020-01005-y. 2021

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Simoes C; (...); Montesinos P

Article. 10.1182/bloodadvances.2020003195. 2021

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Voso MT; (...); Lo-Coco F

Article. 10.1182/bloodadvances.2020002904. 2020

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Stone, RM; (...); Döhner H

Article. 10.1056/NEJMoa1614359. 2017

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

Sierra, Jorge; (...); Venditti, Adriano

Article. 10.1182/bloodadvances.2023009847. 2023

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Larson RA; (...); Stone RM

Article. 10.1038/s41375-021-01179-4. 2021

Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones

Alfonso Pierola, Ana; (...); Prosper, Felipe

Meeting Abstract. 10.1182/blood-2023-188865. 2023

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

Vidriales, MB; (...); PETHEMA Programa Estudio Terapeuti

Article. 10.1016/j.leukres.2015.10.002. 2016

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +/- idasanutlin in relapsed or refractory acute myeloid leukemia

Montesinos, P; (...); Fenaux, P

Article. 10.2217/fon-2020-0044. 2020

MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.

Montesinos, P; (...); Fenaux, P

Meeting Abstract. 2019

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Baron, Frederic; (...); Ciceri, Fabio

Meeting Abstract. 10.1182/blood-2023-186293. 2023

MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL

Gonzalez-Romero, E.; (...); Cervera-Zamora, J.

Meeting Abstract. 2021

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Sirenko, Maria; (...); Papaemmanuil, Elli

Article. 10.1182/blood.2023023723. 2024

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH(1) Acute Myeloid Leukemia

De Botton, Stephane; (...); Fenaux, Pierre

Meeting Abstract. 10.1182/blood-2021-144912. 2021

MOLECULAR CHARACTERIZATION OF ACUTE LEUKAEMIA OF CHILD, ADOLESCENT AND YOUNG ADULT THROUGH MASSIVE GUIDED SEQUENCING

Llop Garcia, M.; (...); Barragan Gonzalez, E.

Meeting Abstract. 2019

MOLECULAR CHARACTERIZATION OF CELLULAR MODELS OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BY MASS SEQUENCING

Navarro, MB; (...); Cervera, J

Meeting Abstract. 2017

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo plus AZA in the AGILE Study

Doehner, Hartmut; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-159473. 2022

Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.

De Botton, Stephane; (...); Dohner, Hartmut

Meeting Abstract. 2022

MOLECULAR CHARACTERIZATION OF PATIENTS WITH HEREDITARY MYELOID NEOPLASIAS THROUGH MASS SEQUENCING

Pardo-Lorente, N.; (...); Cervera, J.

Meeting Abstract. 2018

MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES

Boluda-Navarro, M.; (...); Cervera, J.

Meeting Abstract. 2020

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Rücker FG; (...); Doehner, Konstanze

Article. 10.1038/s41375-021-01323-0. 2021

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.

Sargas, Claudia; (...); On Behalf Of Pethema Group

Article. 10.3390/cancers15020438. 2023

Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Ribera J; (...); Ribera JM

Article. 10.1002/gcc.22788. 2019

Molecular remission as a therapeutic objective in acute promyelocytic leukemia

Cicconi, L; (...); Lo-Coco, F

Review. 10.1038/s41375-018-0219-5. 2018

Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications

Bernard, Elsa; (...); Papaemmanuil, Elli

Meeting Abstract. 10.1182/blood-2023-186863. 2023

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.

Bernard, Elsa; (...); Papaemmanuil, Elli

Article. 10.1182/blood.2023023727. 2024

MONITORING MINIMUM RESIDUAL DISEASE (EMR) THROUGH NGS CONFIRMS PROGNOSTIC VALUE

De La Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients

Olivera, GG; (...); Herrero, MJ

Article. 10.3390/ijms21082714. 2020

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Lin, Chenyu; (...); Horwitz, Mitchell E.

Article. 10.1016/j.jtct.2023.01.031. 2023

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3(mut+)) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Esteve, J; (...); Bahceci, E

Meeting Abstract. 10.1182/blood-2018-99-110976. 2018

Multicentre Implementation of Next Generation Sequencing to Acute Myeloid Leukemia Patients in PETHEMA Spanish Collaborative Group

Sargas, C; (...); Barragan, E

Meeting Abstract. 2019

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

Ramos, F; (...); Spanish Group for Myelodysplastic Syndromes (GESMD)

Article. 10.1002/ajh.24813. 2017

Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases

Artacho, Alejandro; (...); Ubeda, Carles

Article. 10.1186/s40168-024-01948-0. 2024

MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES

Papanicolaou, Genovefa; (...); Hirji, Ishan

Meeting Abstract. 2023

Multiomics Characterization of Normal CD34+Hematopoietic Progenitor Cells (HPC) and Blasts in the Bone Marrow (BM) and Peripheral Blood (PB) of Patients with Acute Myeloid Leukemia (AML)

Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2023-185760. 2023

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

Falantes J; (...); Sanz G

Article. 10.1016/j.leukres.2014.10.004. 2015

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

Dinardo, CD; (...); Vyas, P

Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.7042. 2018

MUTATIONAL PROFILE IN PATIENTS DIAGNOSED WITH LOW-RISK SMD WITHOUT THE RINGED SIDEROBLASTS

Abaigar, M; (...); Campelo, MD

Meeting Abstract. 2018

Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia

Fabiani E; (...); Voso MT

Article. 10.1002/cam4.3904. 2021

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

Cedena, MT; (...); Martinez-Lopez, J

Article. 10.18632/oncotarget.22157. 2017

Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.

Hayashi H; (...); Eurocord, Cellular Therapy & Immunobiology Working Party, and Paediatric Disease

Article. 10.1016/j.bbmt.2019.07.031. 2019

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

Martin, I; (...); Tormo, M

Article. 10.1111/bjh.17675. 2021

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Fenaux, P; (...); ESMO Guidelines Comm

Article. 10.1016/j.annonc.2020.11.002. 2021

NATIONAL EXPERIENCE WITH THE USE OF VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Labrador, J.; (...); Montesinos, P.

Meeting Abstract. 2020

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

Pallares, V; (...); Mangues, R

Article. 10.18632/oncotarget.18537. 2017

Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS)

Martin, I; (...); Sanz, G

Article. 10.1080/10428194.2016.1246725. 2017

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.

Sargas C; (...); Montesinos P

Article. 10.3324/haematol.2020.263806. 2021

NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS

Balaguer Rosello, Aitana; (...); Sanz, Jaime

Meeting Abstract. 2023

NEUTROPHILIA AND ONCOGENE CSF3R MUTATION

Segarra, MG; (...); Alonso, MAS

Meeting Abstract. 2017

NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES

Primo, D.; (...); Ballesteros, J.

Meeting Abstract. 2017

NGS ANALYSIS IN ADULTS GREATER THAN 65 YEARS DIAGNOSED OF ACUTE MYELOID LEUKEMIA IN LOW INTENSITY TREATMENTS

Garcia, AB; (...); Lopez, JM

Meeting Abstract. 2017

Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/II Trial

Horwitz, ME; (...); Sanz, G

Meeting Abstract. 10.1016/j.bbmt.2017.12.628. 2018

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Castano-Bonilla, Tamara; (...); Montesinos, Pau

Article. 10.1155/2022/3132941. 2022

Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Balaguer-Rosello, A; (...); Sanz, Jaime

Article. 10.1016/j.bbmt.2019.05.024. 2019

Non-infectious neurologic complications after allogeneic hematopoietic stem cell transplantation (ALLO-HSCT)

Balaguer Rosello, Aitana; (...); Sanz, Jaime

Meeting Abstract. 2019

Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1038/s41409-021-01537-x. 2022

Non-T Depleted Haploidentical Stem Cell Transplantation in Aml Patients Achieving First Complete Remission After One Vs Two Induction Courses: A Study From The ALWP/EBMT

Nagler, A; (...); Mohty, M

Meeting Abstract. 2021

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.

Nagler, Arnon; (...); Mohty, Mohamad

Article. 10.1186/s13045-023-01450-4. 2023

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023)

Nagler, Arnon; (...); Mohty, Mohamad

Correction. 10.1186/s13045-023-01501-w. 2023

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective.

De Witte T; (...); Smith A

Article. 10.3324/haematol.2020.266817. 2020

Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies studies and correlation with flt3 mutations and polyunsaturated fatty acid metabolism.

Mazzarella L; (...); Pelicci PG

Article. 10.3324/haematol.2019.223925. 2020

OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA

Montesinos, P.; (...); Sanz, M.

Meeting Abstract. 2017

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

Cabrero M; (...); Caballero D

Article. 10.1038/s41409-023-02171-5. 2024

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial

Cabrero, M; (...); Caballero, D

Meeting Abstract. 2020

OLD MATCHED SIBLING DONOR VERSUS YOUNG HAPLOIDENTICAL DONOR FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TRANSPLANTED IN FIRST REMISSION

Poire, Xavier; (...); Ciceri, Fabio

Meeting Abstract. 2024

Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.

Piemontese S; (...); Ciceri F

Article. 10.1038/s41375-024-02359-8. 2024

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Cortes, Jorge E.; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2021-144905. 2021

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

de Botton, Stephane; (...); Cortes, Jorge

Article. 10.1182/bloodadvances.2022009411. 2023

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Cortes, Jorge E.; (...); De Botton, Stephane

Meeting Abstract. 10.1182/blood-2022-167330. 2022

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Watts, Justin M.; (...); Cortes, Jorge E.

Meeting Abstract. 10.1182/blood-2019-123920. 2019

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

Watts, Justin M.; (...); Cortes, Jorge E.

Article. 10.1016/S2352-3026(22)00292-7. 2022

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Cortes, Jorge E.; (...); Olutasidenib Combination Therapy Study Grp

Article. 10.1186/s13045-024-01657-z. 2025

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).

Cortes J; (...); Watts JM

Article. 10.1080/10428194.2024.2333451. 2024

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.

Horwitz, ME; (...); Sanz, G

Article. 10.1182/blood.2021011719. 2021

One or two umbilical cord blood cell units? Caveat emptor

Sanz J, Gale RP

Article. 10.1038/bmt.2016.277. 2017

One-Unit versus Two-Unit Cord-Blood Transplantation

Sanz, J, Sanz, GF, Sanz, MA

Letter. 2015

One-unit versus two-unit cord-blood transplantation.

Sanz J, Sanz GF, Sanz MA

Letter. 2015

OPTIMIZATION OF THE EFFICIENCY OF GENETIC EDITING OF HEMAPOYETIC PROGENITOR CELLS USING CRISPR/CAS9 RIBONUCLEOPROTEINS

Martinez-Valiente, C.; (...); Sanjuan-Pla, A.

Meeting Abstract. 2019

Optimizing Outcomes of Acute Leukemia After Transplants with Single Unrelated Cord Blood Units Selected According to Current International Recommendations for Cell Dose and HLA Match

Rafii, H; (...); Gluckman, E

Meeting Abstract. 2020

Oral Azacitidine (Oral-AZA) improves Overall Survival (OS) and Relapse-free Survival (RFS) for patients with Acute Myeloid Leukemia (AML) in first remission after Intensive Chemotherapy (IC), regardless of amount of consolidation received: Results of the QUAZAR AML-001 maintenance trial

Dohner, H.; (...); Ravandi, F.

Meeting Abstract. 2021

Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Wei, Andrew; (...); Roboz, Gail

Meeting Abstract. 2022

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Wei AH; (...); Roboz GJ

Article. 10.1056/NEJMoa2004444. 2020

Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience.

Sobas M; (...); Giebel S

Article. 10.1016/j.clml.2019.09.616. 2020

Outcome of Acute Myeloid Leukemia with Inv(3)(Q21q26.2)/ T(3;3)(Q21;Q26.2). Experience of the Spanish PETHEMA and CETLAM Groups

Sitges, M; (...); CETLAM Cooperative Grp

Meeting Abstract. 2019

Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT

Heinicke, Thomas; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2023-174233. 2023

Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients

Ferrà C; (...); Ribera JM

Article. 10.3109/10428194.2014.930849. 2015

Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy.

Perez, Ariadna; (...); Pinana, Jose Luis

Article. 10.1007/s15010-024-02213-0. 2024

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

Park, Sophie; (...); Fenaux, Pierre

Letter. 10.1016/j.leukres.2020.106472. 2020

OUTCOME OF LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT 5Q DELETION AFTER FAILURE OF ERYTHROPOIESIS STIMULATING AGENTS

Park, S; (...); Fenaux, P

Meeting Abstract. 10.1016/S0145-2126(17)30162-5. 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Park S; (...); Fenaux P

Article. 10.1200/JCO.2016.71.3271. 2017

Outcome of older (=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Kayser S; (...); Montesinos P

Article. 10.1038/s41375-020-0758-4. 2020

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)

Kayser, Sabine; (...); Montesinos, Pau

Correction. 10.1038/s41375-021-01358-3. 2021

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party

Koenecke, C; (...); Finke, J

Letter. 10.1038/bmt.2016.97. 2016

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Article. 10.3324/haematol.2022.282506. 2024

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.

Caballero, Juan Carlos; (...); Diez Campelo, Maria

Article. 10.1177/20406207231218157. 2024

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

Ribera, JM; (...); PETHEMA Grp

Article. 10.1002/hon.2910. 2021

Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy

Socie, Gerard; (...); Mohty, Mohamad

Article. 10.1038/s41409-023-02127-9. 2024

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

DiNardo, Courtney D.; (...); de Botton, Stephane

Meeting Abstract. 10.1182/blood-2021-147593. 2021

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Venditti, Adriano; (...); Pullarkat, Vinod

Meeting Abstract. 10.1182/blood-2023-182045. 2023

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

Giagounidis A; (...); Fenaux P

Article. 10.1111/ejh.12380. 2014

OUTCOMES OF CAR-T CELL THERAPY FOR LARGE B CELL LYMPHOMA IN PATIENTS OF 70 YEARS AND OLDER: MULTICENTRIC REAL WORLD EXPERIENCE

Bailen, Rebeca; (...); Barba, Pere

Meeting Abstract. 2023

Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.

Baron F; (...); Mohty M

Article. 10.1038/s41409-023-02000-9. 2023

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Shallis, RM; (...); Zeidan, AM

Meeting Abstract. 10.1182/blood-2018-99-119755. 2018

Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.

Rafii, Hanadi; (...); Gluckman, Eliane

Article. 10.1182/bloodadvances.2022007941. 2022

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT

Paviglianiti, A; (...); Mohty, M

Article. 10.3324/haematol.2015.138917. 2016

Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

Ibanez, Mariam; (...); Luna I

Article. 10.3390/diagnostics12040953. 2022

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

Ocio EM; (...); PETHEMA Group

Article. 10.3324/haematol.2015.129577. 2015

PAN-STAKEHOLDER CORE OUTCOME SET (COS) DEFINITION FOR HEMATOLOGICAL MALIGNANCIES IN THE FRAMEWORK OF THE EU PROJECT, HARMONY: THE HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINE OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY

Lang, K.; (...); Bullinger, L.

Meeting Abstract. 2023

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Lang, Katharina M.; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-157549. 2022

Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance

Lang, Katharina M.; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2021-145002. 2021

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.08.020. 2020

Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases

Romero S; (...); Sanz MÁ

Article. 10.2450/2015.0148-14. 2015

Patient Reported Outcomes in Patients with Newly Diagnosed FLT3(mut+) acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone

Wang, Eunice S.; (...); Shah, Manasee V.

Meeting Abstract. 10.1182/blood-2021-144977. 2021

Patient-reported Outcomes in Adults With Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study

Ashaye, Ajibade; (...); Guo, Shien

Meeting Abstract. 2024

PATTERNS OF RESCUE TREATMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED IN THE FIRST LINE WITH AZACITIDINE AND DECITABIN: RESULTS OF THE PETHEMA AML REGISTRY

Jorge, Labrador; (...); Miguel-Angel, Sanz

Meeting Abstract. 2021

PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.

González-Romero E; (...); Vázquez-Manrique RP

Article. 10.3390/cancers15174263. 2023

Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study

Rodriguez-Medina, C; (...); Fernandez, PM

Article. 10.1016/j.leukres.2020.106352. 2020

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Stahl, M; (...); Zeidan, AM

Letter. 10.1080/10428194.2018.1468893. 2019

Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling

Orgueira, AM; (...); Lopez, JLB

Article. 10.3389/fonc.2021.657191. 2021

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Sargas, Claudia; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-166639. 2022

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Review. 10.2174/1389200218666171101124931. 2018

Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016

Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples.

Primo, D; (...); Ballesteros, J

Meeting Abstract. 2017

Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).

Walker, Alison R.; (...); William Burke, Patrick

Meeting Abstract. 2022

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: The DIAMOND-01 trial.

Martinelli, Giovanni; (...); Montesinos, Pau

Meeting Abstract. 2022

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) - Preliminary Blinded Analysis of the European Sintra-REV Trial

Cadenas, FL; (...); Diez-Campelo, M

Meeting Abstract. 10.1182/blood-2018-99-119430. 2018

Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.

Wang, Eunice S.; (...); Tiu, V, Ramon

Article. 10.1182/blood.2021014586. 2022

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Wang, Eunice S.; (...); Tiu, Ramon V.

Meeting Abstract. 10.1182/blood-2021-145379. 2021

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Roboz, Gail J.; (...); Wei, Andrew H.

Letter. 10.1080/10428194.2021.2012667. 2022

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

Horwitz, ME; (...); Sanz, G

Article. 10.1200/JCO.18.00053. 2019

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Daver NG; (...); Kantarjian HM

Article. 10.1016/S1470-2045(23)00674-5. 2024

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2023-173413. 2023

PLZF-RAR(alpha), NPM1-RAR(alpha), and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review

Sobas, M; (...); Montesinos, P

Review. 10.3390/cancers12051313. 2020

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1002/hem3.67. 2024

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA WITH PHILADELPHIA CHROMOSOME. RESULTS OF THE PONALFIL CLINICAL TRIAL WITH COMPLETE RECRUITMENT

Ribera, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2020

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME. PRELIMINARY RESULTS OF THE PONALFIL CLINICAL TRIAL

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2019

PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus ). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2-YEAR FOLLOW-UP

Ribera Santasusana, J. M.; (...); Garcia-Sanz, R.

Meeting Abstract. 2021

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Meeting Abstract. 10.1182/blood-2019-125558. 2019

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph plus ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Aldoss, Ibrahim; (...); Jabbour, Elias

Meeting Abstract. 10.1182/blood-2023-179537. 2023

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Jabbour, Elias; (...); Ribera, Jose-Maria

Article. 10.1001/jama.2024.4783. 2024

Ponatinib, Chemotherapy, and Transplant in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Ribera, Josep-Maria; (...); Garcia-Sanz, Ramon

Article. 10.1182/bloodadvances.2022007764. 2022

POOLED FECAL ALLOGENEIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUSHOST DISEASE: RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE

Malard, Florent; (...); Mohty, Mohamad

Meeting Abstract. 2024

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

Megías-Vericat JE; (...); Aliño SF

Letter. 10.1038/tpj.2015.79. 2016

POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) VERSUS ANTI-THYMOCYTE GLOBULIN (ATG) VERSUS COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT

Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad

Meeting Abstract. 2023

Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC.

Bailen, Rebeca; (...); Kwon, Mi

Article. 10.1016/j.jtct.2022.01.020. 2022

Post-Transplant Cyclophosphamide after HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of Geth-TC

Bailen, Rebeca; (...); Kwon, Mi

Meeting Abstract. 10.1182/blood-2021-150835. 2021

Post-transplant Cyclophosphamide after Matched Sibling and Matched Unrelated Compared to Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Study on Behalf of Geth

Kwon, M; (...); Martin, JLD

Meeting Abstract. 2020

Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT

Sanz, Jaime; (...); Nagler, Arnon

Meeting Abstract. 10.1182/blood-2019-125859. 2019

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.

Sanz J; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp

Article. 10.1186/s13045-020-00882-6. 2020

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.

Lazzari, Lorenzo; (...); Sanz, Jaime

Article. 10.1038/s41409-022-01725-3. 2022

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Sanz, J; (...); Mohty, M

Article. 10.1186/s13045-021-01094-2. 2021

Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.

Bailén R; (...); Díez-Martín JL

Article. 10.1007/s00277-020-04317-7. 2020

Post-transplant cyclophosphamide for GVHD prophylaxis in matched unrelated donor transplantation

Bailen, R; (...); Kwon, M

Meeting Abstract. 2019

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Bailen, Rebeca; (...); Luis Diez-Martin, Jose

Meeting Abstract. 10.1182/blood-2019-124849. 2019

Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.

Wieczorek, Michele; (...); Mohty, Mohamad

Letter. 10.1002/ajh.26782. 2022

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Wieczorek, Michele; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-151087. 2021

Post-transplant cyclophosphamide separates graft-versus host disease (GVHD) and graft versus leukemia (gvl) effects after HLA- matched stem-cell transplantation (sct) for AML

Shimoni, A.; (...); Mohty, M.

Meeting Abstract. 2022

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Battipaglia, Giorgia; (...); Ciceri, Fabio

Meeting Abstract. 10.1182/blood-2024-207391. 2024

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Giebel, Sebastian; (...); Mohty, Mohamad

Article. 10.1002/cncr.35004. 2023

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

Brissot, E; (...); Mohty, M

Article. 10.1186/s13045-020-00923-0. 2020

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with all treated in CR1 with allo-HCT from matched unrelated donors. A study from ALWP of the EBMT

Giebel, S.; (...); Mohty, M.

Meeting Abstract. 2022

Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.

Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad

Article. 10.1002/cncr.35365. 2024

Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation

Dietrich, S; (...); EBMT Lymphoma Working Party

Letter. 10.1038/leu.2016.125. 2016

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

Romero S; (...); Sanz J

Article. 10.1080/10428194.2018.1474462. 2019

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Sahebi, Firoozeh; (...); Schonland, Stefan

Article. 10.1016/j.jtct.2021.09.008. 2021

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Montoro, Juan; (...); Glass, Bertram

Article. 10.1016/j.jtct.2023.11.021. 2024

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1007/s40261-019-00881-7. 2020

Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Abou Dalle, Iman; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2023-187095. 2023

Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?

Review. 10.1080/17474086.2020.1818559. 2020

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Ballesteros, J; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-115849. 2018

Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model

Ferrer-Lores, Blanca; (...); Alberich-Bayarri, Angel

Article. 10.1186/s13550-024-01172-9. 2024

Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy

Abla, O; (...); Sanz, MA

Article. 10.1007/s00277-017-3042-6. 2017

PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY

Cadenas, FL; (...); Diez-Campelo, M

Meeting Abstract. 2017

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Shortt, Jake; (...); Wei, Andrew H.

Meeting Abstract. 10.1182/blood-2022-166937. 2022

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Bazarbachi, Ali; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2023-182823. 2023

Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort The PESA (Progression of Early Subclinical Atherosclerosis) Study

Fernández-Friera L; (...); Fuster V

Article. 10.1161/CIRCULATIONAHA.114.014310. 2015

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.

Cortes JE; (...); Wang ES

Review. 10.1186/s13045-020-00975-2. 2020

Prognosis and Survival of Acute Myeloid Leukemia: Experience of a Single Center in Colombia

Sossa, CL; (...); Jimenez, SI

Meeting Abstract. 10.1182/blood-2018-99-119927. 2018

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Caballero, Teresa; (...); Perez-Simon, Jose A.

Meeting Abstract. 10.1182/blood-2021-151533. 2021

PROGNOSIS VALUE OF MINIMAL DETECTABLE DISEASE (MDD) BY 2(nd) GENERATION ALLOGENIC PRE-TRANSPLANTATION CYTOMETRY IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA

Velazquez Teresa, Caballero; (...); Jose Antonio, Perez Simon

Meeting Abstract. 2021

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study

Kanda, J; (...); Gluckman, E

Meeting Abstract. 2018

Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.

Kanda J; (...); Gluckman E

Article. 10.1038/s41375-019-0534-5. 2020

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.7014. 2021

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

de Swart, L; (...); de Witte, T

Article. 10.1016/j.leukres.2018.01.022. 2018

Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults

Article. 2014

Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy

Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A

Article. 2014

Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

Nomdedeu, M; (...); Costa, D

Article. 10.1002/gcc.22333. 2016

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts

Martin, I; (...); Sanz, G

Article. 10.1038/s41408-017-0016-9. 2017

Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)

Rucker, FG; (...); Dohner, K

Meeting Abstract. 10.1182/blood-2018-99-116149. 2018

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Dohner, Hartmut; (...); de Menezes, Daniel Lopes

Meeting Abstract. 10.1182/blood-2021-147465. 2021

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Dohner, Hartmut; (...); Lopes de Menezes D

Article. 10.1182/blood.2022016293. 2022

Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Uriel Suarez, Edwin; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2022-167365. 2022

PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS

Megias Vericat, J. E.; (...); Sanz, M. A.

Article. 2015

Prognostic Significance of Complex Karyotype and Monosomal Karyotype in Adult Patients With Acute Lymphoblastic Leukemia Treated With Risk-Adapted Protocols

Motlló C; (...); Feliu E

Article. 10.1002/cncr.28950. 2014

Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

Ribera J; (...); Ribera JM

Article. 10.1002/cncr.29579. 2015

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.

Castaño-Bonilla T; (...); Montesinos, P

Article. 10.1038/s41598-021-00050-x. 2021

Prognostic Value of Chromosome 1 Abnormalities in Myelodysplastic Syndrome

Ibarrondo, Paloma; (...); Batlle-Lopez, Ana

Article. 2014

PROGNOSTIC VALUE OF EARLY DROP IN PLATELETS IN LOWER-RISK MDS. A SUB-STUDY FROM THE EUROPEAN LEUKEMIANET LOWER-RISK MDS (EUMDS) REGISTRY

Itzykson, R; (...); de Witte, T

Meeting Abstract. 10.1016/S0145-2126(17)30132-7. 2017

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.

Caballero-Velazquez, Teresa; (...); Perez-Simon, Jose A.

Article. 10.3390/cancers15051609. 2023

PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS

Liquori, A.; (...); Cervera Zamora, J.

Meeting Abstract. 2021

Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.

Sanz J; (...); Piñana JL

Article. 10.1016/j.bbmt.2019.10.014. 2020

PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT.

Montoro J; (...); Glass B

Article. 10.1182/bloodadvances.2024013328. 2024

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia

Pinana, JL; (...); Navarro, D

Article. 10.1016/j.jinf.2019.02.009. 2019

Pulmonary invasive fungal disease after community acquire respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients: Results from a prospective observational study

Pinana, Jose; (...); Navarro, David

Meeting Abstract. 2019

Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Marco-Ayala J; (...); Solves P

Review. 10.1038/s41409-020-01124-6. 2021

qMetforminintreatment Overcomes AT-Resistance in Acute Promyelocytic Leukemia Foxo3A Expression

Pereira-Martins, DA; (...); Rego, EM

Meeting Abstract. 10.1182/blood-2018-99-115068. 2018

Quality of thawed plasma inactivated with methylene blue after 48-hour storage

Balaguer A; (...); Sanz MÁ

Letter. 10.1016/j.transci.2014.11.005. 2015

QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)

Levis, Mark J.; (...); Perl, Alexander E.

Meeting Abstract. 2023

Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Levis, Mark J.; (...); Perl, Alexander

Meeting Abstract. 10.1182/blood-2022-162739. 2022

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction ( IND) and Consolidation CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)

Perl, Alexander; (...); Levis, Mark J.

Meeting Abstract. 10.1182/blood-2023-186785. 2023

QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients

Perl, Alexander E.; (...); Levis, Mark J.

Meeting Abstract. 2024

QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Erba, Harry P.; (...); Montesinos, Pau

Meeting Abstract. 2024

QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Schlenk, R; (...); Erba, H

Meeting Abstract. 2017

QuANTUM-R: phase 3, randomised trial of Quizartinib in patients with FLT3-Internal tandem duplication (FLT3-ITD)-positive relapsed/refractory (R/R) acute myeloid meukaemia (AML)

Radsak, M. P.; (...); Levis, M. J.

Meeting Abstract. 2019

Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results

Cortes, JE; (...); Levis, MJ

Meeting Abstract. 10.1093/annonc/mdz374.003. 2019

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

Erba, Harry P.; (...); Schlenk, Richard F.

Article. 10.1016/S0140-6736(23)00464-6. 2023

Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML

Schlenk, R.; (...); Erba, H.

Meeting Abstract. 2022

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, JE; (...); Levis, MJ

Article. 10.1016/S1470-2045(19)30150-0. 2019

Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis

Vallejo C; (...); Rayón C

Article. 10.1007/s00277-015-2305-3. 2015

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Cortes, JE; (...); Heuser, M

Article. 10.1038/s41375-018-0312-9. 2019

Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis

Garcia-Manero, Guillermo; (...); Yacoub, Abdulraheem

Meeting Abstract. 2023

RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Garcia-Manero, G.; (...); Yacoub, A.

Meeting Abstract. 10.1016/j.leukres.2023.107270. 2023

Rapid and Robust CD4+and CD8+T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

Boelens, JJ; (...); Nierkens, S

Meeting Abstract. 10.1182/blood-2018-99-116700. 2018

Rapid and Robust CD4+and CD8+T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation

de Koning, Coco; (...); Boelens, Jaap-Jan

Meeting Abstract. 2019

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Voso, MT; (...); Lo-Coco, F

Meeting Abstract. 10.1182/blood-2018-99-114318. 2018

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )

Falantes, J; (...); European ALMA?+?Investigators

Article. 10.1080/10428194.2017.1365854. 2018

Real life outcomes of patients aged =75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.

Salamero O; (...); PETHEMA and PALG Groups

Article. 10.1080/10428194.2019.1607327. 2019

Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Saiz-Rodriguez, M; (...); Pethema Grp

Meeting Abstract. 2021

REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID

Jorge, Labrador; (...); Pau, Montesinos

Meeting Abstract. 2021

Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.

Asensi Cantó P; (...); Gómez-Seguí I

Article. 10.1016/j.jtct.2023.09.001. 2023

Real-world experience with CPX-351 in high-risk acute myeloid leukemia.

Lemoli, Roberto M., Montesinos, Pau, Jain, Akriti

Article. 10.1016/j.critrevonc.2023.103984. 2023

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged = 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Requena, Gaspar Aspas; (...); Matinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-190128. 2023

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Sauta, Elisabetta; (...); Della Porta, Matteo G.

Meeting Abstract. 10.1182/blood-2022-163634. 2022

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Sauta, Elisabetta; (...); Della Porta, Matteo Giovanni

Article. 10.1200/JCO.22.01784. 2023

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.

Hernandez-Sanchez, Alberto; (...); Bullinger, Lars

Article. 10.1038/s41375-024-02333-4. 2024

Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Hernandez Sanchez, Alberto; (...); Bullinger, Lars

Meeting Abstract. 10.1182/blood-2022-167480. 2022

Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015

Gonzalez, J; (...); Cohort Spanish HIV Res Network Co

Article. 10.1016/j.eimc.2019.02.007. 2019

Recent advances in allogeneic transplantation for acute myeloid leukemia.

Montoro J, Balaguer-Roselló A, Sanz J

Article. 10.1097/CCO.0000000000000992. 2023

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Spyridonidis A; (...); Mohty M

Article. 10.1038/s41409-020-0803-y. 2020

Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.07.008. 2023

Reduced Intensity (RIC) vs Myeloablative Conditioning (MAC) in Cord Blood Transplantation for AML (40-60 Years) Across Mismatched HLA Barriers - Analysis by Ctiwp/eurocord of EBMT

Sheth, V; (...); Ruggeri, A

Meeting Abstract. 2020

Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia.

Weinhäuser I; (...); Rego EM

Article. 10.3390/cancers12113134. 2020

Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Baron F; (...); Mohty M

Article. 10.1002/cncr.29163. 2015

Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation

Baron, Frederic; (...); Nagler, Arnon

Article. 2015

Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.

Sheth V; (...); Ruggeri A

Article. 10.1016/j.bbmt.2020.07.025. 2020

Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.

Montesinos, Pau; (...); Heuser, Michael

Article. 10.3390/cancers16101824. 2024

REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?

Santiago, Marta; (...); Cervera, Jose

Meeting Abstract. 2020

Reply.

Lozano Almela, Maria Luisa, Sanz Alonso, Miguel Angel, Vicente Garcia, Vicente

Letter. 10.1016/j.medcli.2021.09.029. 2022

RESCUE TREATMENT WITH DECITABINE AFTER PROGRESSION TO AZACITIDINE IN AML

De la Fuente, A; (...); Montesinos, P

Meeting Abstract. 2018

RESPONSE TO AZACITIDINE IN A SERIES OF 94 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES

Triguero, A; (...); Sanz, G

Meeting Abstract. 10.1016/S0145-2126(17)30232-1. 2017

Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria*

Triguero, A.; (...); Sanz, G.

Article. 10.1016/j.leukres.2022.106836. 2022

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia

Xicoy B; (...); Sanz G

Article. 10.1111/ejh.12679. 2016

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Roboz, Gail J.; (...); Dohner, Hartmut

Meeting Abstract. 10.1182/blood-2021-147769. 2021

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Kantarjian, Hagop M.; (...); Chiao, Judy H.

Article. 10.1002/cncr.33828. 2021

RESULTS OF HLA IDENTICAL ALLOGENIC TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS HAPLOIDENTIAL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: EXPERIENCE OF THE SPANISH HAEMATOPOIETIC TRANSPLANT GROUP (GETH)

Almorox Rebeca, Bailen; (...); Mi, Kwon

Meeting Abstract. 2021

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.

Torrent, Anna; (...); Ribera, Josep-Maria

Article. 10.1111/ejh.14031. 2023

RESULTS OF THE TREATMENT OF LYMPHOBLASTIC LYMPHOMA WITH PROTOCOLS OF LYMPHOBLASTIC ACUTE LEUKEMIA OF PETHEMA GROUP

Sagues, M.; (...); Ribera, J. M.

Meeting Abstract. 2019

Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation

Solves, P; (...); Sanz, G

Letter. 10.1016/j.transci.2019.02.002. 2019

RETROSPECTIVE STUDY OF AZACITIDINE IN PATIENTS OF ADVANCED AGE WITH ACUTE MYELOID LEUKEMIA (LMA). RESULTS OF THE ALMA/ PETHEMA COHORT IN COMPARISON WITH THE MRC RISK INDEX SCORE

Falantes, J.; (...); Ramos, F.

Meeting Abstract. 2015

Revealing the mutational landscape of acute promyelocytic leukemia

Cervera, J, Sanz, MA

Editorial Material. 10.21037/tcr.2017.02.47. 2017

Review of Cutaneous Graft-vs-Host Disease.

Ballester-Sánchez R; (...); Botella-Estrada R

Article. 10.1016/j.ad.2015.10.003. 2016

Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification.

Angenendt, Linus; (...); Schliemann, Christoph

Article. 10.1182/blood.2022018582. 2022

RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT

Baron, F; (...); Nagler, A

Article. 10.18632/oncotarget.9599. 2016

Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.

Montoro, Juan; (...); Pinana, Jose Luis

Letter. 10.1038/s41409-020-01161-1. 2020

Risk of Rh (D) alloimmunisation after Rh (D) positive platelet transfusions in patients undergoing haematopoietic stem cell transplantation

Solves P; (...); Sanz MA

Letter. 10.1111/tme.12179. 2015

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Ribera, Josep-Maria; (...); Sancho, Juan-Manuel

Meeting Abstract. 10.1182/blood-2019-125683. 2019

RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib

Such, E; (...); Cervera, J

Article. 10.1159/000497348. 2019

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.

Mussetti, Alberto; (...); Sureda, Anna

Article. 10.1038/s41409-023-01949-x. 2023

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Mussetti, Alberto; (...); Sureda, Anna

Meeting Abstract. 10.1182/blood-2022-160000. 2022

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Ribera, Jordi; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2023-186265. 2023

Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.

Review. 10.3389/fonc.2021.614215. 2021

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Paiva, B; (...); Montesinos, P

Meeting Abstract. 10.1182/blood-2018-99-113299. 2018

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.

Pinto-Merino, Alvaro; (...); Saiz-Rodriguez, Miriam

Article. 10.3390/pharmaceutics14030559. 2022

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.

Escamilla Gómez V; (...); Pérez-Simón JA

Article. 10.1038/s41409-019-0731-x. 2020

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Zeidan, Amer M.; (...); Garcia-Manero, Guillermo

Meeting Abstract. 10.1182/blood-2021-145626. 2021

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Daver, Naval; (...); Sweet, Kendra

Meeting Abstract. 10.1182/blood-2021-146503. 2021

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Montesinos P; (...); Wei AH

Article. 10.1038/s41375-020-0773-5. 2020

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Review. 10.1007/s00277-018-3304-y. 2018

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

Vives, Susana; (...); PETHEMA Grp

Article. 10.3390/cancers16234028. 2024

Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.

Moles-Poveda, P; (...); Botella-Estrada, R

Article. 10.1016/j.ad.2017.11.003. 2018

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using PostTransplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Sanz, Jaime; (...); Ciceri, Fabio

Meeting Abstract. 10.1182/blood-2023-180075. 2023

SCREENING FOR POTENTIAL THERAPEUTIC OPPORTUNITIES FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH IKZF1 DELETIONS

Ribera, Jordi; (...); Ribera, Josep Maria

Meeting Abstract. 2020

Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation.

Piñana JL; (...); Infectious Diseases Working Party of the European Society for Blood and Marrow T

Article. 10.1093/infdis/jiaa553. 2020

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia

Kharfan-Dabaja, MA; (...); Mohty, M

Article. 10.1111/bjh.17426. 2021

SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT2) FOR PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE LEUKEMIA IN REMISSION: ON BEHALF OF THE ALWP OF THE EBMT

Nagler, Arnon; (...); Mohty, Mohamad

Meeting Abstract. 2023

Secondary Acute Myeloid Leukemia from a Previous Chronic Myeloproliferative Neoplasm: A Study of Grelam-Chile Concerning Chilean Patients on Behalf of AML Pethema Registry

Espinoza, Marcela; (...); Martinez-Cuadron, David

Meeting Abstract. 10.1182/blood-2023-185288. 2023

Secondary and Therapy-Related Acute Promyelocytic Leukemia. Experience of the PETHEMA Registry

Montesinos, P; (...); GATLA Cooperative Grp

Meeting Abstract. 2017

Secondary neoplasms after umbilical cord blood transplantation. On behalf of eurocord and the european group for blood and marrow transplantation

El Ayoubi, H. Rafii; (...); Gluckman, E.

Meeting Abstract. 2022

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Paoli, Alessandro; (...); Pellacani, Andrea

Meeting Abstract. 10.1182/blood-2021-150277. 2021

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.

Cortes JE; (...); Heuser M

Review. 10.1080/10428194.2020.1817445. 2020

Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT.

Kharfan-Dabaja, Mohamed A.; (...); Mohty, Mohamad

Article. 10.1097/HS9.0000000000000920. 2023

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Torrent, Anna; (...); Ribera, Josep-Maria

Meeting Abstract. 10.1182/blood-2024-207954. 2024

Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT

Baron, F; (...); Nagler, A

Article. 10.1186/s13045-017-0497-9. 2017

Single umbilical cord blood with or without CD34(+) cells from a third-party donor in adults with leukemia.

Sanz, J; (...); Grp Espanol Trasplante

Article. 10.1182/bloodadvances.2017006999. 2017

SINTRA-REV CLINICAL TRIAL: PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY AT WEEK 12 OF TREATMENT IN MDS DEL(5Q) AND TRANSFUSION INDEPENDENCE

Cadenas, FL; (...); Diez-Campelo, M

Meeting Abstract. 2017

Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.

Hernani, Rafael; (...); Solano, Carlos

Article. 10.1002/jha2.183. 2021

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

Weinhauser, I; (...); Rego, EM

Meeting Abstract. 10.1182/blood-2018-99-115370. 2018

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.

Risueno, Alberto; (...); Hasan, Maroof

Article. 10.1016/j.leukres.2024.107497. 2024

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Palomo L; (...); Such E

Article. 10.1111/bjh.16175. 2020

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Zeidan, AM; (...); Mascarenhas, J

Review. 10.1016/S2352-3026(20)30205-2. 2020

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Shallis RM; (...); Zeidan AM

Article. 10.1016/S2352-3026(23)00159-X. 2023

Starkeya nomas sp. nov., a prosthecate and budding bacterium isolated from an immunocompromized patient.

Sahuquillo-Arce JM; (...); López-Hontangas JL

Article. 10.1099/ijsem.0.005805. 2023

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)+azacitidine in higher risk MDS and CMML-2.

Zeidan AM; (...); Santini V

Article. 10.2217/fon-2022-1237. 2023

STUDY OF CHRONIC ANEMIA IN THE ELDERLY

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

STUDY OF MUTATIONAL PROFILE AND CORRELATION OF RESPONSE TO EX VIVO PHARMACOLOGICAL TEST, IN THE DIAGNOSTIC OF THE AML

de la Fuente, EO; (...); Diaz, RA

Meeting Abstract. 2018

STUDY OF PRE-EXISTING MUTATIONS IN HEMATOPOYETIC CELLS OF THE BONE MEDULA IN PATIENTS WITH MYELOID NEOPLASIAS RELATED TO THERAPY

Ibanez, M; (...); Sanz, G

Meeting Abstract. 2017

STUDY OF THE CELL POPULATIONS INFUSED IN THE TRANSPLANT ALOGENICO OF BROTHER HLA-IDENTICAL

Villalba, A.; (...); Sanz, M. A.

Meeting Abstract. 2017

STUDY OF THE EFFECTIVENESS OF IMATINIB IN CHRONIC GRAFT-VERSUS-HOST DISEASE IN A SERIES OF 19 CASES

Poveda, PM; (...); Caballer, JS

Meeting Abstract. 2017

Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia

Dolz S; (...); Barragán E

Article. 10.3109/10428194.2015.1049167. 2016

STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS

Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente

Meeting Abstract. 2020

Summer Pruning, an Eco-Friendly Approach to Controlling Bitter Pit and Preserving Sensory Quality in Highly Vigorous Apple cv. 'Reinette du Canada'

Guerra, Marcos; (...); Antonio Casquero, Pedro

Article. 10.3390/agriculture11111081. 2021

Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia

Melo, CLS; (...); Montesinos, P

Meeting Abstract. 2021

Survival of Patients with Acute Myeloid Leukemia, Taken to Hematopoietic Stem Cell Transplantation: Experience of A Center in Colombia

Melo, CLS; (...); Ortiz, MF

Meeting Abstract. 2021

Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia

Ortiz, MF; (...); Sossa, C

Meeting Abstract. 2021

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Cortes, JE; (...); Heuser, M

Article. 10.1186/s13045-020-00929-8. 2020

Survival Outcomes for Patients (pts) in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine (Oral-AZA) or Placebo (PBO)

Pfeilstoecker, M.; (...); Doehner, H.

Meeting Abstract. 2023

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Ravandi, Farhad; (...); Doehner, Hartmut

Meeting Abstract. 10.1182/blood-2022-159045. 2022

Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)

Pfeilstoecker, Michael; (...); Menezes, Daniel

Meeting Abstract. 2022

Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.

Ravandi, Farhad; (...); Roboz, Gail J

Article. 10.1111/bjh.19202. 2023

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial.

Wei AH; (...); Ravandi F

Article. 10.3324/haematol.2022.282296. 2023

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Review. 10.3390/pharmaceutics14040878. 2022

T lymphocytes as therapeutic arsenal for patients with hematological malignancies

Montoro, J; (...); Guerreiro, M

Review. 10.1097/CCO.0000000000000481. 2018

T REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH SECONDARY VERSUS DE NOVO AML: A STUDY FROM THE ALWP /EBMT

Nagler, Arnon; (...); Mohty, Mohamad

Meeting Abstract. 2023

t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

Ribera, J; (...); Ribera, JM

Meeting Abstract. 2021

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

Sanford D; (...); Cortes JE

Article. 10.1111/bjh.13607. 2015

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Martín-Sánchez E; (...); Zabaleta A

Article. 10.1182/bloodadvances.2024013212. 2024

TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT

Swoboda, R.; (...); Mohty, M.

Meeting Abstract. 2022

T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.01.016. 2023

T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis

Gorin NC; (...); Acute Leukemia Working Party of the European Society for Blood and Marrow Transp

Article. 10.3324/haematol.2014.111450. 2015

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

Pigneux, A; (...); Bruggemann, M

Article. 10.1186/s12885-018-5002-5. 2018

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)

Montesinos, P; (...); Delgado, J

Letter. 10.1038/bmt.2016.145. 2016

The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation.

Piñana J; (...); Sanz J

Article. 10.1016/j.jinf.2019.12.022. 2020

THE COMBINATION OF GENOMIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IMPROVES THE STRATIFICATION OF ADULT PATIENTS WITH TYPE T-LYMPHOBLASTIC LEUKEMIA (LAL-T) TREATED ACCORDING TO THE PETHEMA PROTOCOLS

Gonzalez Gil, C.; (...); Genesca Ferrer, E.

Meeting Abstract. 2021

The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation.

Shouval R; (...); Nagler A

Meeting Abstract. 10.1182/blood-2019-123310. 2019

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS

Xicoy, Blanca; (...); Sanz, Guillermo

Letter. 10.1016/j.leukres.2018.05.003. 2018

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey.

Piñana JL; (...); Navarro D

Article. 10.1038/s41409-019-0698-7. 2020

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

Lange, AP; (...); Rego, EM

Letter. 10.1111/bjh.14490. 2018

The First Real-World Evidence Prospective Registry of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp, a CD123-Targeted Therapy, in Europe

Platzbecker, Uwe; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2021-145099. 2021

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Mosquera Orgueira, Adrian; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-180482. 2023

The Impact of Cytogenetic Risk on Outcome of Non-T Cell Depleted Haploidentical Stem Cell Transplantation in Relapsed/Refractory AML: A Study From The ALWP/EBMT

Nagler, A; (...); Mohty, M

Meeting Abstract. 2021

The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and CoOccurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party

Dalle, Abou; (...); Mohty, Mohamad

Meeting Abstract. 10.1182/blood-2023-179531. 2023

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Rubio MT; (...); Mohty M

Article. 10.3324/haematol.2014.119339. 2015

The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.

Kanda, Junya; (...); Gluckman, Eliane

Article. 10.1038/s41409-021-01479-4. 2022

The Impact of GVHD on Outcomes After Adult Single Cord Blood Transplantation In European And Japanese Populations: The EUROCORD/ALWP EBMT And JSHCT/JDCHCT Collaborative Study

Kanda, J; (...); Gluckman, E

Meeting Abstract. 2021

The Interaction Between Collagen-Activated Platelets and Erythrocytes Selectively Increases the Release of Subsets of Platelet alpha-Granules Containing Pro-Angiogenic Substances

Teresa Santos, Maria; (...); Valles, Juana

Meeting Abstract. 2014

The modular network structure of the mutational landscape of Acute Myeloid Leukemia

Ibanez, M; (...); Cervera, J

Article. 10.1371/journal.pone.0202926. 2018

THE MODULAR NETWORK STRUCTURE OF THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA

Ibanez, M.; (...); Cervera, J.

Article. 2015

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Ayala, R; (...); Montesinos, P

Article. 10.3390/cancers13102458. 2021

The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations

Ibáñez, M; (...); Cervera, J.

Article. 10.1371/journal.pone.0148346. 2016

The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

Ribera, J; (...); Ribera, JM

Article. 10.1111/bjh.15887. 2019

The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission

Dohner, H; (...); Roboz, GJ

Meeting Abstract. 2020

The role of phototherapy in cutaneous chronic graft-vs-host disease: a retrospective study and review of the literature.

Ballester-Sánchez R; (...); Botella-Estrada R

Article. 10.1016/j.ad.2015.04.009. 2015

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients.

Villar, Sara; (...); Montesinos, Pau

Article. 10.3389/fonc.2022.1054458. 2022

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Kuendgen, A; (...); Sanz, G

Meeting Abstract. 10.1182/blood-2018-99-118215. 2018

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Kuendgen A; (...); Sanz G

Article. 10.1038/s41375-020-0917-7. 2020

Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Eder, S; (...); Nagler, A

Article. 10.1002/ajh.24567. 2017

Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Eder S; (...); Nagler A

Article. 10.1002/ajh.24823. 2017

Thiotepa-based reduced-intensity conditioning are a valid alternative to total-body irradiation-based regimens in patients with acute lymphoblastic leukemia: A study of the alwp of the ebmt

Battipaglia, G.; (...); Mohty, M.

Meeting Abstract. 2022

Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Battipaglia, Giorgia; (...); Mohty, Mohamad

Article. 10.1016/j.jtct.2023.09.028. 2024

Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain

Boluda, B; (...); Montesinos, P

Article. 10.1007/s41669-018-0098-8. 2019

Time-dependent changes in mortality and transformation risk in MDS

Pfeilstocker, M; (...); Greenberg, PL

Article. 10.1182/blood-2016-02-700054. 2016

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.

Jonas, Brian A.; (...); Ofran, Yishai

Article. 10.1002/ajh.26600. 2022

Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy

Benzaquen, Ana; (...); Solano, Carlos

Article. 10.1038/s41409-023-02114-0. 2024

TORQUE TENO VIRUS PLASMA DNA LOAD: A NOVEL PROGNOSTIC BIOMARKER IN CAR-T THERAPY

Hernani, Rafael; (...); Solano, Carlos

Meeting Abstract. 2023

Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.

Mora E; (...); Sanz J

Article. 10.1038/s41409-024-02298-z. 2024

Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Efficace, Fabio; (...); Zeidan, Amer M

Article. 10.1002/hem3.69. 2024

Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS

De La Serna, J; (...); Spanish Hematopoietic Transplant

Article. 10.1038/bmt.2016.42. 2016

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Patricia Simoes, Catia; (...); Paiva, Bruno

Meeting Abstract. 10.1182/blood-2022-163159. 2022

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Simoes, Catia; (...); Montesinos, Pau

Letter. 10.1111/bjh.18815. 2023

TRANSCRIPTIONAL CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA AT DIAGNOSIS IN THE ELDERLY PATIENT WITH IDENTIFICATION OF NEW PROGNOSTIC GROUPS

Sara, Villar; (...); Pau, Montesinos

Meeting Abstract. 2021

TRANSCRIPTOMICAL ANALYSIS AND MODELING IN C.ELEGANS OF THE IDH2 R140 R172 MUTATION

Gonzalez-Romero, E.; (...); Cervera-Zamora, J., V

Meeting Abstract. 2019

Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.

Solves, Pilar; (...); Sanz, Jaime

Article. 10.3390/jcm12103467. 2023

Transfusion Management and Immunohematologic Complications in Liver Transplantation: Experience of a Single Institution

Solves P; (...); Sanz MÁ

Article. 10.1159/000370260. 2015

Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.

Solves P; (...); Carpio N

Article. 10.1016/j.transci.2019.09.011. 2020

Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation

Solves P; (...); Sanz MA

Article. 10.2450/2015.0195-14. 2015

TRANSFUSIONAL REQUIREMENTS OF PATIENTS UNDERGOING TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS OF DIFFERENT SOURCES

Blanco, JA; (...); Alonso, MAS

Meeting Abstract. 2018

Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.

Klepin HD; (...); Cordoba R

Review. 10.1016/j.jgo.2020.03.019. 2020

Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

Ribera, JM; (...); Spanish Soc Hematology

Article. 10.1016/j.clml.2020.03.011. 2020

Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment

Montesinos P; (...); Sanz MÁ

Article. 10.1016/j.riam.2014.10.003. 2015

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Martinez-Cuadron, David; (...); Montesinos, Pau

Meeting Abstract. 10.1182/blood-2023-189800. 2023

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Lloret-Madrid, Pilar; (...); Montesinos, Pau

Article. 10.1002/cncr.35696. 2025

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1182/bloodadvances.2021005335. 2022

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Diez-Campelo, Maria; (...); Valcarcel, David

Meeting Abstract. 10.1182/blood-2021-146019. 2021

Trends and Predictive Factors for Outcome of Relapsed Acute Myeloid Leukemia After Allogeneic Hematopoeitic Cell Transplant: Improved Survival for Young Patients in Recent Years

Bazarbachi, A; (...); Mohty, M

Meeting Abstract. 2020

TRENDS IN THE USE OF HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

Giebel, Sebastian; (...); Ciceri, Fabio

Meeting Abstract. 10.1007/s00277-019-03771-2. 2024

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?